Sihuan Pharmaceutical H1 profit jumps on medical aesthetics unit strength

Sihuan Pharmaceutical Holdings

26/08/2026 05:15

Overview
China pharmaceutical group's interim revenue rose 1.3% yr/yr, led by medical aesthetics growth
Net income attributable to shareholders jumped 119% yr/yr, driven by medical aesthetics segment
Company profit growth aided by narrowing losses in innovative medicine and subsidiary disposal gain

Outlook
Company did not provide specific financial outlook

Result Drivers
MEDICAL AESTHETICS GROWTH - Revenue and profit growth were mainly driven by an 18.5% increase in medical aesthetics sales, particularly from stable demand for core products and higher sales of regenerative and functional products
NARROWING INNOVATIVE MEDICINE LOSSES - Losses in the innovative medicine segment narrowed significantly as commercialization advanced, supporting overall profit improvement
SUBSIDIARY DISPOSAL GAIN - Profit was aided by a RMB154.2 mln gain from the disposal of a subsidiary, which offset losses from other segments

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 1.16 bln
 
H1 Net Income Attributable
 
RMB 224.70 mln
 

Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 16 three months ago

Reuters Recommended Reads
Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth
Aug 25 - China's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)